Outlook Therapeutics, Inc. (Nasdaq: OTLK), today announced the Scottish Medicines Consortium (SMC) approval of LYTENAVA™ (bevacizumab gamma) for the treatment of wet age-related macular degeneration ...

GLP-1 RA use was linked to a 2.21-fold risk of developing neovascular age-related macular degeneration// (nAMD) * Only 0.2% ...

A new study found a link between GLP-1s and a higher risk of neovascular age-related macular degeneration, an eye disease ...

"Receiving the SMC recommendation of LYTENAVA™ (bevacizumab gamma) for patients with wet AMD is a significant milestone for our company and a testament to our commitment to improving patient outcomes, ...

Age-related macular degeneration (AMD) is a major cause of blindness, especially in older adults. A key feature of early AMD ...

Semaglutide, widely used to treat diabetes and obesity, was associated with more than double the risk of developing ...

The gift will be used to treat and potentially cure eye diseases like macular degeneration and glaucoma, increase focus on ...

Jay Chhablani, MD, explains how 3D choroidal vessel segmentation transforms ophthalmology, enhancing disease diagnosis and treatment through advanced imaging technology.

Purpose To assess the extended efficacy and safety of suprachoroidal triamcinolone acetonide injectable suspension (CLS-TA) among patients with macular oedema (ME ... support suprachoroidal CLS-TA as ...